Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

Study Overview

This study compares two treatments for advanced-stage classic Hodgkin’s lymphoma:

Brentuximab vedotin combined with AVD (BV+AVD)
Nivolumab combined with AVD (N+AVD)

Brentuximab can improve outcomes but may lead to more side effects and challenges with relapses. Nivolumab has shown effectiveness, especially in previously untreated patients.

Trial Details

In this phase 3 trial, 994 patients aged 12 and older with newly diagnosed stage III or IV Hodgkin’s lymphoma were randomly assigned to receive either treatment. The main goal was to measure progression-free survival, which means the time until the disease worsens or the patient dies.

Results

Out of 994 patients, 970 were included in the analysis:

After a median follow-up of 12.1 months, N+AVD showed significantly better progression-free survival than BV+AVD, with a hazard ratio of 0.48 (indicating a lower risk of disease progression or death).
With a longer follow-up of 2.1 years, 92% of patients on N+AVD were still free of disease progression, compared to 83% for those on BV+AVD (hazard ratio of 0.45).
Only 7 patients received radiation therapy, and nivolumab had fewer immune-related side effects compared to brentuximab, which led to more treatment stoppages.

Key Takeaways

N+AVD offers:

Longer progression-free survival: Better outcomes for patients with stage III or IV Hodgkin’s lymphoma.
Fewer side effects: A more manageable treatment experience for patients.

Practical Solutions and Value

Clinical trials are crucial for advancing safe treatments. To make this knowledge accessible, our AI-driven platform, DocSym, consolidates clinical standards and research.

In today’s healthcare landscape, optimizing operations is vital. Our mobile applications facilitate: